NASDAQ · SHPH
Healthcare · Drug Manufacturers - Specialty & Generic
$3.48
Up+$0.02 (+0.57%)
Updated Sep 5, 2026, 12:39 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SHPH closed at $3.48 after 20 trading sessions, down 20.18% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $3.50 | $3.565 | $3.4005 | $3.48 | 11.78K |
| Sep 2, 2026 | $3.59 | $3.65 | $3.42 | $3.49 | 24.57K |
| Sep 1, 2026 | $3.37 | $4.10 | $3.37 | $3.61 | 153.41K |
| Aug 31, 2026 | $3.50 | $3.62 | $3.36 | $3.36 | 51.99K |
| Aug 28, 2026 | $3.69 | $3.74 | $3.50 | $3.54 | 55.31K |
| Aug 27, 2026 | $3.75 | $3.99 | $3.6301 | $3.88 | 125.13K |
| Aug 26, 2026 | $3.44 | $3.624 | $3.44 | $3.59 | 427.08K |
| Aug 25, 2026 | $3.51 | $3.56 | $3.2906 | $3.44 | 14.24K |
| Aug 24, 2026 | $3.74 | $3.74 | $3.51 | $3.52 | 16.3K |
| Aug 21, 2026 | $3.72 | $3.84 | $3.6632 | $3.76 | 10.43K |
| Aug 20, 2026 | $3.69 | $3.79 | $3.5301 | $3.71 | 21.39K |
| Aug 19, 2026 | $4.00 | $4.3499 | $3.70 | $3.76 | 18.56K |
| Aug 18, 2026 | $4.06 | $4.10 | $3.87 | $3.92 | 45.85K |
| Aug 17, 2026 | $4.04 | $4.3295 | $4.0258 | $4.10 | 46.54K |
| Aug 14, 2026 | $4.61 | $4.61 | $4.0051 | $4.07 | 44.36K |
| Aug 13, 2026 | $4.19 | $4.80 | $4.19 | $4.58 | 94.7K |
| Aug 12, 2026 | $4.33 | $4.33 | $4.12 | $4.23 | 16.02K |
| Aug 11, 2026 | $4.06 | $4.32 | $3.9428 | $4.31 | 20.55K |
| Aug 10, 2026 | $4.21 | $4.21 | $3.8901 | $4.07 | 36.04K |
| Aug 7, 2026 | $4.51 | $4.5399 | $4.32 | $4.36 | 57.41K |
The latest Smart Investors Daily articles mentioning SHPH.
SHPH research
Company profile and research snapshot.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 3, 2026
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding (NASDAQ:SLBT)
Benzinga · Aug 3, 2026
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus Pharmaceuticals
Benzinga · Jul 31, 2026
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is at
ChartMill · Jul 20, 2026
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SHPH.
